Assessment Sarcopenia, Serum Interleukin-6, Alpha 1-Antichymotrypsin and Other biomarker in Female Patients with rheumatoid Arthritis Akram Raghda Shams1,*, Al-Najar Adnan F.1, Joda Abbas Toma1 1College of Medicine, Al-Mustansiriyah University *Correspondence Author: Raghda Shams Akram, College of Medicine, Al-Mustansiriyah University, Email: raghda336@gmail.com
Online published on 4 June, 2019. Abstract Objective Assessment of muscle bulk, sarcopenia, skeletal muscle mass index (SMI), serum interleukin-6 (IL-6), Alpha 1-antichymotrypsin, myoglobin, and C-reactive protein between female patients with RA and healthy control groups. Method Eighty eight subjects, fifty eight female patients with RA (age 42.0 ± 6.0 years) and thirty female control (age 41.8 ± 6.1 years) were enrolled in this study. Skeletal muscle mass index (SMI) was measured with dual-energy X-ray absorptiometry (DXA). IL-6 and a1-ACT, myoglobin, and C-reactive protein were measured in serum by using ELISA. Results Study showed that SMI in patients with RA were significantly lower than that in the healthy controls, serum Myoglobin level these was no significant difference in RA patients from controls, The serum CRP level in RA patients were significantly higher than that in the healthy controls and the same was also for serum IL-6 level. In addition, Patients with RA showed a significant increased level of serum alpha-1 ACT compared to healthy controls. Conclusion the risk of sarcopenia is higher in RA patients in comparison to healthy controls of the same age. SMI was significantly lower in RA patient's compared to healthy controls. There is no significant changes in serum myoglobin in RA patients compared to healthy controls because myoglobin level changes is closely associated with muscle damage but not muscle mass loss. There is a significant increase in serum CRP, IL-6 and ACT in RA patients compared to healthy control. Top Keywords Rheumatoid arthritis, sarcopenia, SMI, IL-6, ACT, Myoglobin, CRP. Top |